Stock analysts at StockNews.com initiated coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the ...

After being diagnosed with multiple myeloma, Valarie Traynham turned her journey into a mission—raising awareness, educating ...

Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) ...

Dr Vivek Verma, Associate Director-Surgical Oncology, Max Super Speciality Hospital Patparganj highlights that pediatric ...

IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma ...

Researchers sought to determine whether CAR-T therapy with ide-cel would be effective in patients with triple-class–exposed relapsed/refractory MM.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S.

The collaboration will drive cord blood-derived allogeneic CAR T-cell development. Singapore General Hospital (SGH) has ...

According to Auletta, addressing these disparities requires a collective, ecosystem-wide effort in order to ensure better representation and access for vulnerable patients in stem cell transplants and ...

The CAR T-cell therapy market size was valued at $2.6 billion in 2022 & is estimated to hit $35.9 billion by 2032, exhibiting a CAGR of 28 ...

PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus ...

This roundup highlights a common drug that can help treat multiple myeloma, a paper analyzing the benefit of a colorectal surgery follow-up test ...